Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The Company’s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. It has two late-stage anti-infective product candidates: fidaxomicin (formerly OPT-80) and prulifloxacin. Fidaxomicin, the Company’s lead product candidate, is an antibiotic in its second Phase III registration trial for the treatment of Clostridium difficile-infections (CDI), the common nosocomial, or hospital acquired diarrhea. Prulifloxacin is a prodrug in the fluoroquinolone class of antibiotics. The Company is developing additional product candidates using its technology, including its Optimer One-Pot Synthesis (OPopS) drug discovery platform. OPopS is a computer-aided technology that enables the rapid and low-cost synthesis of an array of carbohydrate-based compounds.
(Source: 10-K) – less–ZoomInfo